2-溴-n-(3-甲基苯基)乙酰胺 | 5439-17-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-溴-n-(3-甲基苯基)乙酰胺
• 中文别名: 乙酰胺,N-(3-甲基苯基)-2-溴-
• 英文名称: 2-bromo-N-(m-tolyl)acetamide
• 英文别名: 2-bromo-N-(3-methylphenyl)acetamide
• CAS: 5439-17-8
• 化学式: C₉H₁₀BrNO
• mdl: MFCD02974383
• 分子量: 228.088
• InChiKey: FSQVBULEPAWPNF-UHFFFAOYSA-N

物化性质

• 保留指数：
  1622

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2924299090

反应信息

• 作为反应物：
  描述：

  2-溴-n-(3-甲基苯基)乙酰胺 在 palladium on activated charcoal 氢气 、 potassium carbonate 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 20.0 ℃ 、413.68 kPa 条件下， 反应 34.0h， 生成 2-[4-(5-hydroxypyridin-2-yl)piperidin-1-yl]-N-(3-methylphenyl)acetamide
  参考文献：
  名称：

  Discovery of 3-Methyl-N-(1-oxy-3‘,4‘,5‘,6‘-tetrahydro-2‘H-[2,4‘-bipyridine]-1‘-ylmethyl)benzamide (ABT-670), an Orally Bioavailable Dopamine D₄ Agonist for the Treatment of Erectile Dysfunction

  摘要：

  The goal of this study was to identify a structurally distinct D-4-selective agonist with superior oral bioavailability to our first-generation clinical candidate 1a (ABT-724) for the potential treatment of erectile dysfunction. Arylpiperazines such as (heteroarylmethyl) piperazine 1a, benzamide 2, and acetamides such as 3a,b exhibit poor oral bioavailability. Structure-activity relationship (SAR) studies with the arylpiperidine template provided potent partial agonists such as 4d and 5k that demonstrated no improvement in oral bioavailability. Further optimization with the (N-oxy-2-pyridinyl) piperidine template led to the discovery of compound 6b (ABT-670), which exhibited excellent oral bioavailability in rat, dog, and monkey (68%, 85%, and 91%, respectively) with comparable efficacy, safety, and tolerability to 1a. The N-oxy-2-pyridinyl moiety not only provided the structural motif required for agonist function but also reduced metabolism rates. The SAR study leading to the discovery of 6b is described herein.

  DOI：

  10.1021/jm060662k
• 作为产物：
  描述：

  溴乙酰氯 、 3-甲基苯胺 在 sodium hydroxide 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 0.5h， 以52%的产率得到2-溴-n-(3-甲基苯基)乙酰胺
  参考文献：
  名称：

  （2-芳基-1-哌嗪基）-N-（3-甲基苯基）乙酰胺的合成和功能活性：选择性多巴胺D4受体激动剂。

  摘要：

  二芳基哌嗪乙酰胺被确定为有效的和选择性的多巴胺D（4）受体激动剂。我们的策略基于对酸敏感的多巴胺D（4）受体部分激动剂PD 168077的酰胺键逆转。这种逆转为化合物提供了出色的效能和更高的稳定性。芳基哌嗪部分取代的系统评价显示对功能活性的显着影响。这些新的多巴胺D（4）激动剂的合成和生物学活性进行了讨论。

  DOI：

  10.1016/j.bmc.2004.04.035

文献信息

• Acetamides and benzamides that are useful in treating sexual dysfunction
  申请人：——

  公开号：US20040029887A1

  公开（公告）日：2004-02-12

  The present invention relates to the use of compounds of formula (I) 1 for the treatment of sexual dysfunction and to compositions containing compounds of formula (I) for the treatment of sexual dysfunction.

  本发明涉及使用式(I)的化合物治疗性功能障碍，以及含有式(I)化合物的组合物用于治疗性功能障碍。
• [EN] TRICYCLIC PYRAZOLE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASES A BASE DE TYRAZOLES TRICYCLIQUES
  申请人：ABBOTT LAB

  公开号：WO2005095387A1

  公开（公告）日：2005-10-13

  Compounds of the present invention are useful for inhibiting protein tyrosine kinases. Also disclosed are methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

  本发明的化合物对抑制蛋白酪氨酸激酶具有用处。还公开了制备这些化合物的方法、含有这些化合物的组合物以及使用这些化合物进行治疗的方法。
• Synthesis and α-Glucosidase Inhibition Activity of 2-[3-(Benzoyl/4-bromobenzoyl)-4-hydroxy-1,1-dioxido-2H-benzo[e][1,2]thiazin-2-yl]-N-arylacetamides: An In Silico and Biochemical Approach
  作者：Furqan Ahmad Saddique、Sana Aslam、Matloob Ahmad、Usman Ali Ashfaq、Muhammad Muddassar、Sadia Sultan、Saman Taj、Muzammil Hussain、Dae Sung Lee、Magdi E. A. Zaki

  DOI：10.3390/molecules26103043

  日期：——

  Diabetes mellitus (DM) is a chronic disorder and has affected a large number of people worldwide. Insufficient insulin production causes an increase in blood glucose level that results in DM. To lower the blood glucose level, various drugs are employed that block the activity of the α-glucosidase enzyme, which is considered responsible for the breakdown of polysaccharides into monosaccharides leading to an increase in the intestinal blood glucose level. We have synthesized novel 2-(3-(benzoyl/4-bromobenzoyl)-4-hydroxy-1,1-dioxido-2H-benzo[e][1,2]thiazin-2-yl)-N-arylacetamides and have screened them for their in silico and in vitro α-glucosidase inhibition activity. The derivatives 11c, 12a, 12d, 12e, and 12g emerged as potent inhibitors of the α-glucosidase enzyme. These compounds exhibited good docking scores and excellent binding interactions with the selected residues (Asp203, Asp542, Asp327, His600, Arg526) during in silico screening. Similarly, these compounds also showed good in vitro α-glucosidase inhibitions with IC50 values of 30.65, 18.25, 20.76, 35.14, and 24.24 μM, respectively, which were better than the standard drug, acarbose (IC50 = 58.8 μM). Furthermore, a good agreement was observed between in silico and in vitro modes of study.

  糖尿病（DM）是一种慢性疾病，已经影响了全球大量人口。胰岛素产量不足导致血糖水平升高，从而引发糖尿病。为了降低血糖水平，使用了各种药物来阻断α-葡萄糖苷酶的活性，该酶被认为是将多糖分解为单糖，导致肠道血糖水平升高的原因。我们合成了新型的2-(3-(苯甲酰/对溴苯甲酰)-4-羟基-1,1-二氧化-2H-苯并[e][1,2]噻嗪-2-基)-N-芳基乙酰胺，并对它们进行了体外和体内α-葡萄糖苷酶抑制活性的筛选。衍生物11c、12a、12d、12e和12g显示出对α-葡萄糖苷酶的强效抑制作用。这些化合物在体外筛选过程中表现出良好的对接得分，并与所选残基（Asp203、Asp542、Asp327、His600、Arg526）展现出优秀的结合相互作用。同样，这些化合物在体内也表现出良好的α-葡萄糖苷酶抑制作用，其IC50值分别为30.65、18.25、20.76、35.14和24.24 μM，优于标准药物阿卡波糖（IC50 = 58.8 μM）。此外，在体内和体外研究模式之间观察到了良好的一致性。
• Design, synthesis of novel (Z)-2-(3-(4-((3-benzyl-2,4-dioxothiazolidin-5-ylidene)methyl)-1-phenyl-1H-pyrazol-3-yl)phenoxy)-N-arylacetamide derivatives: Evaluation of cytotoxic activity and molecular docking studies
  作者：Prashanth Kumar Kolluri、Nirmala Gurrapu、N.J.P. Subhashini、Shravani Putta、Surya Sathyanarayana Singh、Tamalapakula Vani、Vijjulatha Manga

  DOI：10.1016/j.molstruc.2019.127300

  日期：2020.2

  the screened derivatives demonstrated moderate to promising cytotoxic activity. Some of the derivatives, particularly compound 11d and 11n have shown promising cytotoxic activity with IC50 values 0.604 μM and 0.665 μM compared to standard drug cisplatin and compounds 11a, 11e and 11g also have shown considerable cytotoxic activity and the rest of the derivatives have shown moderate activity. Furthermore

  摘要 为了发现潜在的细胞毒剂，一系列新型 (Z)-2-(3-(4-((3-benzyl-2,4-dioxothiazolidin-5-ylidene)methyl)-1-phenyl-1H -吡唑-3-基)苯氧基)-N-芳基乙酰胺衍生物11a-n在不同的步骤中以可接受的反应程序以良好的产率合成，并通过1H NMR、13C NMR、IR和ESI-MS光谱表征。评估了所有新合成衍生物对人乳腺细胞系 (MCF-7) 的细胞毒活性，浓度分别为 0.625 μM、1.25 μM、2.5 μM、5 μM 和 10 μM。生物学评价测定结果以细胞活力降低的百分比和IC50值显示。大多数筛选的衍生物表现出中等至有希望的细胞毒活性。一些衍生品，特别是化合物 11d 和 11n 显示出有希望的细胞毒活性，与标准药物顺铂相比，IC50 值为 0.604 μM 和 0.665 μM，化合物 11a、11e 和 11g
• [EN] SPIROCYCLIC COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES<br/>[FR] COMPOSÉS SPIROCYCLIQUES ET LEUR UTILISATION COMME AGENTS THÉRAPEUTIQUES ET SONDES DE DIAGNOSTIC
  申请人：UNIV BASEL

  公开号：WO2011114275A1

  公开（公告）日：2011-09-22

  The invention relates to new triazines (G = Q = U are N), pyrimidines (two out of G, Q and U are N), and pyridopyrimidines (one of G and U together with R2 forms an anullated pyridine ring) of formula (I) carrying a spirocyclic substituent, wherein E1 is CR4 or N; X1 is CHR4, CH2CH2, NR4, NR4→0, or O; and the other substituents are as defined in the specification. The compounds inhibit phosphoinositide 3-kinase (PI3K), mammalian target of rapamycin (mTOR), DNA-PK and ATM kinase, and may be used as therapeutic agents or diagnostic probes. The invention also relates to methods of using the compounds for treatment of associated pathological conditions.

  本发明涉及新的三嗪类化合物（其中G = Q = U为N）、嘧啶类化合物（其中G、Q和U中的两个为N）和吡啶嘧啶类化合物（其中G和U中的一个与R2共同形成一个环状吡啶环），它们都带有一个螺环取代基，化学式为（I）。其中，E1为CR4或N；X1为CHR4、CH2CH2、NR4、NR4→0或O；其他取代基如规范中所定义。这些化合物能够抑制磷脂酰肌醇3-激酶（PI3K）、哺乳动物雷帕霉素靶蛋白酶（mTOR）、DNA-PK和ATM激酶，并可用作治疗剂或诊断探针。本发明还涉及使用这些化合物治疗相关病理条件的方法。